Assessment of efficiency of change of inhibitor of angiogenesis at a takhifilaksiya of a neovascular age makulyarny degeneration to systematic antiangiogenic therapy
One of possible ways of overcoming a takhifilaksiya to antiangiogenic medicines at patients with a neovascular age makulyar degeneration is medicine change. The short-term assessment of efficiency of change of antiangiogenic medicine in actual practice was a research objective. Two groups of examinees with a neovascular age makulyarny degeneration and indications to the 6 th injection of inhibitor of angiogenesis are created. In the first group (7 patients, 9 eyes) carried out intravitrealny introduction of an aflibercept at an interval of a month, in the second group (8 patients, 8 eyes) - each 2 months. Estimated visual acuity according to tables of Early Treatment Diabetic Retinopathy Study, thickness of the central retina according to an optical coherent tomography. At patients of the first group in 1 month after the 2 nd intravitrealny introduction of an aflibercept visual acuity significantly hasn’t changed: increase according to tables of ETDRS has made 1±6 signs. Thickness of the central retina opposite has authentically decreased (p<0,05) by 137±223 microns. At patients of the second group in 1 month after the 2nd intravitrealny introduction of an aflibercept of significant changes of visual acuity according to tables of Early Treatment Diabetic Retinopathy Study hasn’t occurred (p>0,05). Unlike the first group of reliable reduction of thickness of the central retina it is noted, average decrease has made 24±82 microns (p>0,05). Thus change of medicine for antiangiogenic therapy doesn’t give increase in visual functions. At the same time, monthly introduction of an aflibercept leads to significant decrease in thickness of the central retina and provides significantly the best anatomic result, than introduction at an interval of two months that can affect visual acuity maintenance duration in the long term.